

Boosting the anti-inflammatory potential of naringin as a nano-nutraceutical

Andreia Marinho^{1,2}, Salette Reis¹, Cláudia Nunes^{1,3*}

¹LAQV, REQUIMTE, Faculdade de Farmácia, Universidade do Porto, R. Jorge de Viterbo Ferreira 228, 4050-313 Porto, Portugal

²LAQV, REQUIMTE, Faculdade de Ciências, Universidade do Porto, R. Campo Alegre s/n, 4169-007 Porto, Portugal

³LAQV, REQUIMTE, Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, R. Jorge de Viterbo Ferreira 228, 4169-007 Porto, Portugal


*cdnunes@ff.up.pt

1 BACKGROUND


Inflammation is a vital **defense response**. In normal conditions it is a fast process, however, if not properly regulated, it can lead to **chronic inflammatory conditions**.

Compounds like **naringin (NAR)** from grapefruit have **anti-inflammatory effects** but limited clinical use due to low bioavailability. **Nanotechnology with lipid nanoparticles enhances NAR efficacy**, allowing controlled release and modulation of inflammatory mediators, promoting new nutraceuticals and functional foods.

2 PROBLEM



3 STRATEGY




4 RESULTS

DYNAMIC LIGHT SCATTERING CHARACTERIZATION


Formulation	Size (nm)	PDI	Zeta (mV)	% EE
NPs	591.2 ± 25.4	0.06 ± 0.03	-25.82 ± 1.52	-
NAR@NPs	592.5 ± 17.9	0.147 ± 0.038	-25.31 ± 1.45	≈30%
NPs _{CTAB}	284.6 ± 1.4	0.156 ± 0.013	24.18 ± 1.12	-
NAR@NPs _{CTAB}	286.1 ± 2.6	0.208 ± 0.070	28.66 ± 1.70	≈36%
NPs _{HA}	432.6 ± 4.8	0.197 ± 0.02	9.06 ± 0.55	-
NAR@NPs _{HA}	431.0 ± 37.4	0.245 ± 0.040	9.94 ± 1.72	≈35%

The differences in values between the two techniques may indicate that there is HA that does not bind to the nanoparticles

NANOPARTICLE TRACKING ANALYSIS




RELEASE STUDY




Controlled release of naringin in the presence of nanoparticles

CELL VIABILITY STUDIES – THP-1 CELL LINE




Positive charge of nanoparticles influences cell viability

HEMOLYSIS ASSAY




There is no hemolytic activity for concentrations of at least 0.50 µg/mL

UPTAKE STUDY



Uptake time-dependence for both formulations
In the case of NLC_{HA} there may be a saturation of the CD44 receptor (further studies are needed)

ANTI-INFLAMMATORY ACTIVITY



IL-1β ↓ IL-6 ↓ TNF-α ↓



This work aligns with SDG 3 by enhancing naringin's therapeutic efficacy for better health outcomes and disease prevention, and with SDG 12 by using nanotechnology to improve nutraceutical efficiency and promote sustainable production.

ACKNOWLEDGMENTS: A.M. acknowledges the funding of Project Norte-08-5369-FSE-000050. CN thanks FCT (Fundação para a Ciência e Tecnologia) for funding through the Individual Call to Scientific Employment Stimulus (2022.05608.CEECIND). This work received financial support from FCT/MCTES (UIDB/50006/2020 DOI 10.54499/UIDB/50006/2020) through national funds.



ESTIG/IPB, Bragança
24-25 July 2024